Biotech · Public company · South San Francisco, CA, US

Alx Oncology Holdings Inc

Ticker ALXO · SEC CIK 0001810182

Track this companyFree. Adds Alx Oncology Holdings Inc to your Dealase workspace and tells you when its record changes.

Clinical trials125 recruiting or active

Pipeline programs27From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline27

Evorpacept (ALX148)Phase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
RamucirumabPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 3 · Gastric CancerClinicalTrials.gov · fetched Nov 12, 2026
CapecitabinePhase 2 · Breast Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
Cisplatin/Carboplatin; 5FUPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
EribulinPhase 2 · Breast Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
evorpaceptPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
Evorpacept (ALX148)Phase 2 · Breast Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Breast Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
PaclitaxelPhase 2 · Breast Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
pembrolizumabPhase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 2 · Breast Cancer, MetastaticClinicalTrials.gov · fetched Nov 12, 2026
5-FU + CisplatinPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
ALX2004Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
azacitidinePhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
azacitidinePhase 1 · Higher Risk Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
Enfortumab VedotinPhase 1 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
evorpaceptPhase 1 · Higher Risk Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
evorpaceptPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
EvorpaceptPhase 1 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
Evorpacept (ALX148)Phase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
Ramucirumab + PaclitaxelPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
TrastuzumabPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
venetoclaxPhase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials12

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerPHASE2 · RECRUITING · started Dec 10, 2025ClinicalTrials.gov NCT07007559 · fetched Nov 12, 2026
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsPHASE1 · RECRUITING · started Aug 18, 2025ClinicalTrials.gov NCT07085091 · fetched Nov 12, 2026
PRE-ISPY Phase I/II Oncology Platform ProgramPHASE1_PHASE2 · RECRUITING · started Feb 15, 2023ClinicalTrials.gov NCT05868226 · fetched Nov 12, 2026
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)PHASE1 · COMPLETED · started Nov 2, 2022ClinicalTrials.gov NCT05524545 · fetched Nov 12, 2026
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerPHASE2 · TERMINATED · started Jul 28, 2022ClinicalTrials.gov NCT05167409 · fetched Nov 12, 2026
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)PHASE2_PHASE3 · COMPLETED · started Jan 15, 2022ClinicalTrials.gov NCT05002127 · fetched Nov 12, 2026
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerPHASE1_PHASE2 · COMPLETED · started Sep 15, 2021ClinicalTrials.gov NCT05027139 · fetched Nov 12, 2026
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)PHASE2 · ACTIVE_NOT_RECRUITING · started May 10, 2021ClinicalTrials.gov NCT04675333 · fetched Nov 12, 2026
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)PHASE1 · TERMINATED · started May 5, 2021ClinicalTrials.gov NCT04755244 · fetched Nov 12, 2026
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 2, 2021ClinicalTrials.gov NCT04675294 · fetched Nov 12, 2026
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)PHASE1 · TERMINATED · started Oct 2, 2020ClinicalTrials.gov NCT04417517 · fetched Nov 12, 2026
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)PHASE1 · COMPLETED · started Feb 3, 2017ClinicalTrials.gov NCT03013218 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 11, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 13, 2026 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Mar 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Feb 27, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jan 30, 2026 · fetched Nov 12, 2026